The purpose of this study is to evaluate the efficacy and safety of Zanidatamab plus CisGem (Cisplatin and Gemcitabine) with or without the addition of a programmed death protein 1/ligand-1 (PD-1/L1) inhibitor (physician's choice of either Durvalumab or Pembrolizumab, where approved under local regulations) as first line of treatment for participants with human epidermal growth factor receptor 2 (HER2)-positive biliary tract cancer.
Biliary Tract Cancer, HER2 Gene Mutation
The purpose of this study is to evaluate the efficacy and safety of Zanidatamab plus CisGem (Cisplatin and Gemcitabine) with or without the addition of a programmed death protein 1/ligand-1 (PD-1/L1) inhibitor (physician's choice of either Durvalumab or Pembrolizumab, where approved under local regulations) as first line of treatment for participants with human epidermal growth factor receptor 2 (HER2)-positive biliary tract cancer.
Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract Cancer
-
Rocky Mountain Cancer Centers, LLP, Lone Tree, Colorado, United States, 80124
AdventHealth Hematology and Oncology, Orlando, Florida, United States, 32804
Winship Cancer Institute, Atlanta, Georgia, United States, 30322
The University of Kansas Cancer Center - Westwood, Westwood, Kansas, United States, 66205
Norton Cancer Institute - Audubon, Louisville, Kentucky, United States, 40217
Ochsner Clinic Foundation, New Orleans, Louisiana, United States, 70121
University of Michigan Hospital, Ann Arbor, Michigan, United States, 48109
Henry Ford Health System, Detroit, Michigan, United States, 48202
Minnesota Oncology Hematology, P.A., Maple Grove, Minnesota, United States, 55369
Atlantic Health System/Morristown Medical Center, Morristown, New Jersey, United States, 07960
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
For general information about clinical research, read Learn About Studies.
18 Years to
ALL
No
Jazz Pharmaceuticals,
2029-11-01